A review of onabotulinumtoxinA (Botox).

Z. Paul Lorenc; Jeffrey M. Kenkel; Steven Fagien; Haideh Hirmand; Mark S. Nestor; Anthony P. Sclafani; Jonathan M Sykes; Heidi A. Waldorf

doi:10.1177/1090820X12474629

A review of onabotulinumtoxinA (Botox).

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M Sykes, Heidi A. Waldorf

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.

Original language	English (US)
Journal	Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery
Volume	33
Issue number	1 Suppl
DOIs	https://doi.org/10.1177/1090820X12474629
State	Published - Mar 2013
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1177/1090820X12474629

Cite this

A review of onabotulinumtoxinA (Botox). / Lorenc, Z. Paul; Kenkel, Jeffrey M.; Fagien, Steven; Hirmand, Haideh; Nestor, Mark S.; Sclafani, Anthony P.; Sykes, Jonathan M; Waldorf, Heidi A.

In: Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, Vol. 33, No. 1 Suppl, 03.2013.

Research output: Contribution to journal › Article › peer-review

@article{a6eb03e4343b4e94bec993f51fc3f001,

title = "A review of onabotulinumtoxinA (Botox).",

abstract = "OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.",

author = "Lorenc, {Z. Paul} and Kenkel, {Jeffrey M.} and Steven Fagien and Haideh Hirmand and Nestor, {Mark S.} and Sclafani, {Anthony P.} and Sykes, {Jonathan M} and Waldorf, {Heidi A.}",

year = "2013",

month = mar,

doi = "10.1177/1090820X12474629",

language = "English (US)",

volume = "33",

journal = "Aesthetic Surgery Journal",

issn = "1090-820X",

publisher = "SAGE Publications Inc.",

number = "1 Suppl",

}

TY - JOUR

T1 - A review of onabotulinumtoxinA (Botox).

AU - Lorenc, Z. Paul

AU - Kenkel, Jeffrey M.

AU - Fagien, Steven

AU - Hirmand, Haideh

AU - Nestor, Mark S.

AU - Sclafani, Anthony P.

AU - Sykes, Jonathan M

AU - Waldorf, Heidi A.

PY - 2013/3

Y1 - 2013/3

N2 - OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.

AB - OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.

UR - http://www.scopus.com/inward/record.url?scp=84882937423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882937423&partnerID=8YFLogxK

U2 - 10.1177/1090820X12474629

DO - 10.1177/1090820X12474629

M3 - Article

C2 - 23515199

AN - SCOPUS:84882937423

VL - 33

JO - Aesthetic Surgery Journal

JF - Aesthetic Surgery Journal

SN - 1090-820X

IS - 1 Suppl

ER -

A review of onabotulinumtoxinA (Botox).

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this